Minocycline prevents osmotic demyelination associated with aquaresis

Kidney International

Volumn 86, Issue 5, 2014, Pages 954-964

  Takagi, Hiroshi ^a   Sugimura, Yoshihisa ^a   Suzuki, Haruyuki ^a   Iwama, Shintaro ^a   Izumida, Hisakazu ^a   Fujisawa, Haruki ^a   Ogawa, Koichiro ^a   Nakashima, Kotaro ^a   Ochiai, Hiroshi ^a   Takeuchi, Seiji ^a   Kiyota, Atsushi ^a   Suga, Hidetaka ^a   Goto, Motomitsu ^a   Banno, Ryoichi ^a   Arima, Hiroshi ^a   Oiso, Yutaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

hyponatremia; ODS; SIADH; vasopressin

Indexed keywords

AQUAPORIN 4; CHEMOKINE; CYTOKINE; DESMOPRESSIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRIX METALLOPROTEINASE; MINOCYCLINE; SODIUM CHLORIDE; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR; AQP4 PROTEIN, RAT; ARGIPRESSIN[1 DEAMINO]; BENZAZEPINE DERIVATIVE; BIOLOGICAL MARKER; NEUROPROTECTIVE AGENT; SODIUM; VASOPRESSIN RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUARESIS; ARTICLE; ASTROCYTE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIURESIS; ELECTROLYTE DISTURBANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; MALE; NEUROLOGIC DISEASE; NONHUMAN; NONPARAMETRIC TEST; OSMOTIC DEMYELINATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADVERSE EFFECTS; ANIMAL; ANIMAL BEHAVIOR; BLOOD; BRAIN; CELL PROTECTION; CHEMICALLY INDUCED; DEMYELINATING DISEASES; DISEASE MODEL; DRUG EFFECTS; ELECTROLYTE BALANCE; GENETICS; INTRACRANIAL HEMORRHAGES; METABOLISM; OSMOSIS; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; AQUAPORIN 4; ASTROCYTES; BEHAVIOR, ANIMAL; BENZAZEPINES; BIOLOGICAL MARKERS; BRAIN; CHEMOKINES; CYTOKINES; CYTOPROTECTION; DEAMINO ARGININE VASOPRESSIN; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DIURESIS; HYPONATREMIA; INTRACRANIAL HEMORRHAGES; MALE; MATRIX METALLOPROTEINASES; MINOCYCLINE; NEUROPROTECTIVE AGENTS; OSMOSIS; RATS, SPRAGUE-DAWLEY; SALINE SOLUTION, HYPERTONIC; SODIUM; THERAPEUTICS; TIME FACTORS; WATER-ELECTROLYTE BALANCE;

EID: 84908606565     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.119     Document Type: Article

References (40)

1. Anderson RJ, Chung HM, Kluge R, et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102: 164-168
2. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013; 126: S1-S42
3. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4: 1522-1530
4. Kleinschmidt-DeMasters BK, Norenberg MD. Rapid correction of hyponatremia causes demyelination: relation to central pontine myelinolysis. Science 1981; 211: 1068-1070
5. Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009; 76: 587-589
6. Kamel KS, Halperin ML. Managing overly rapid correction of chronic hyponatremia: an ounce of prevention or a pound of cure? J Am Soc Nephrol 2010; 21: 2015-2016
7. Kamel KS, Halperin ML. The importance of distal delivery of filtrate and residual water permeability in the pathophysiology of hyponatremia. Nephrol Dial Transplant 2012; 27: 872-875
8. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112
9. Verbalis JG, Adler S, Schrier RW, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164: 725-732
10. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-Term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343
11. Gines P. Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol 2007; 46: 1150-1152
12. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712
13. Gross PA, Wagner A, Decaux G. Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet. Kidney Int 2011; 80: 594-600
14. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-1589
15. Gankam Kengne F, Soupart A, Pochet R, et al. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int 2009; 76: 614-621
16. Soupart A, Penninckx R, Crenier L, et al. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int 1994; 45: 193-200
17. Silver SM, Schroeder BM, Sterns RH, et al. Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats. J Neuropathol Exp Neurol 2006; 65: 37-44
18. Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991; 88: 303-309
19. Soupart A, Coffernils M, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-Term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012; 7: 742-747
20. Suzuki H, Sugimura Y, Iwama S, et al. Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia. J Am Soc Nephrol 2010; 21: 2090-2098
21. Gankam-Kengne F, Soupart A, Pochet R, et al. Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol 2010; 21: 2099-2108
22. Baker EA, Tian Y, Adler S, et al. Blood-brain barrier disruption and complement activation in the brain following rapid correction of chronic hyponatremia. Exp Neurol 2000; 165: 221-230
23. Sugimura Y, Murase T, Takefuji S, et al. Protective effect of dexamethasone on osmotic-induced demyelination in rats. Exp Neurol 2005; 192: 178-183
24. Frydenlund DS, Bhardwaj A, Otsuka T, et al. Temporary loss of perivascular aquaporin-4 in neocortex after transient middle cerebral artery occlusion in mice. Proc Natl Acad Sci USA 2006; 103: 13532-13536
25. Blocher J, Eckert I, Elster J, et al. Aquaporins AQP1 and AQP4 in the cerebrospinal fluid of bacterial meningitis patients. Neurosci Lett 2011; 504: 23-27
26. Iwama S, Sugimura Y, Suzuki H, et al. Time-dependent changes in proinflammatory and neurotrophic responses of microglia and astrocytes in a rat model of osmotic demyelination syndrome. Glia 2011; 59: 452-462
27. Gankam Kengne F, Nicaise C, Soupart A, et al. Astrocytes are an early target in osmotic demyelination syndrome. J Am Soc Nephrol 2011; 22: 1834-1845
28. Miyazaki T, Yamamura Y, Onogawa T, et al. Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia. Endocrinology 2005; 146: 3037-3043
29. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-867
30. Rojiani AM, Prineas JW, Cho ES. Protective effect of steroids in electrolyteinduced demyelination. J Neuropathol Exp Neurol 1987; 46: 495-504
31. Wake H, Moorhouse AJ, Miyamoto A, et al. Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci 2013; 36: 209-217
32. Soupart A, Penninckx R, Stenuit A, et al. Treatment of chronic hyponatremia in rats by intravenous saline: comparison of rate vs. magnitude of correction. Kidney Int 1992; 41: 1662-1667
33. Verbalis JG, Martinez AJ. Neurological and neuropathological sequelae of correction of chronic hyponatremia. Kidney Int 1991; 39: 1274-1282
34. Giannetti AV, Pittella JE. Ischemic and hemorrhagic necrosis of the pons with anatomical location similar to that of central pontine myelinolysis in a chronic alcoholic patient. Clin Neuropathol 1993; 12: 156-159
35. Imoto S, Takeda A, Koyama K, et al. Late occurrence of severe hyponatremia followed by extrapontine osmotic demyelination syndrome after successful conservative management of postpartum hemorrhage due to placenta accreta by uterine artery embolization. J Matern-Fetal Neonatal Med 2010; 23: 742-746
36. Ruiz-Sandoval JL, Chiquete E, Alvarez-Palazuelos LE, et al. Atypical forms of the osmotic demyelination syndrome. Acta Neurol Belg 2013; 113: 19-23
37. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314: 1535-1542
38. Papadopoulos MC, Verkman AS. Aquaporin water channels in the nervous system. Nat Rev Neurosci 2013; 14: 265-277
39. Moe SE, Sorbo JG, Sogaard R, et al. New isoforms of rat Aquaporin-4. Genomics 2008; 91: 367-377
40. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661